A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Name: A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors
Published: 2008
License: Public Domain

Eisai Inc. · 2008

ClinicalTrials.gov · Datasets · License: Public Domain · 2008

Open Source ↗

leukemia therapy

leukemia, anc, bmt, graft versus leukemia, graft vs. host disease, md2 (endotoxin binding-protein), undergo allogeneic bmt, myeloablative, conditioning, therapy, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Related documents